However, the ATM status-dependent specificity of PARP inhibitor sensitivity recently came into question, when it was shown that the PARP1/2 inhibitor talazoparib (BMN-673) displayed activity against CLL cells ex vivo independent of ATM and HR status56. This evidence concerns the gene ATM and B-cell chronic lymphocytic leukemia.